ALABAMA BOARD OF PHARMACY
BUSINESS MEETING MINUTES
AUGUST 19, 2026

President Thomas H. Cobb called the August 19, 2026, meeting of the Alabama Board of Pharmacy to order at 9:03 a.m. to conduct necessary business. The meeting was held at the office of the Alabama Board of Pharmacy, 111 Village Street, Birmingham, Alabama 35242.

The following Board members were present:

Thomas H. Cobb	President
Stacy S. Giles	Vice President
Johnny Brooklere	Treasurer
Brandon Hicks	Member
Darrelle Knight Marbury	Member
Jeb Mitchell	Member
Alecia Booker	Member
Honorable Freddie Stokes	Member
Nathan Pinner	Member

Alabama Board of Pharmacy staff members present in person or via WebEx teleconference were:

Aaron Dettling, Gen. Counsel, Disciplinary Division	Anne Marie Nolen, Admin. Supervisor
Scott Daniel, Gen. Counsel, Administrative Division	Rebecca Tindle, Licensing Supervisor
Jon Linna, Executive Secretary	Wendy Passmore, Operations Manager
Susan Alverson, Dir. of Regulatory Affairs	Patty Wright, Complaints, Investigation
Casey Shaw, Chief Investigator/HR	Terry Lawrence, IT Manager
Todd Brooks, Investigator	Phyllis Mathis, Receptionist

Members of the public present in person or via WebEx teleconference were:

James Driskell	Krystyne Douglass	Berkley Sykes
Logan Gray	Louise Jones	Lea Wolsoncroft
Mary-Coleman Roberts	Meredith Townsend	Brenda Denson
Ron Hartman	Paul Menasco	Josh Hardin
Kristin Brown	Jacey Cox	Dan Gillis
Christy Bolt	Dan McConaghy	Joseph Brooks
Rachel Burell	Alhaji Jalloh	Vicki Walker
James Driskell	Carrie Kreps	Starla Gamble
Heather Hughes	Allison Souders	Brad Hamilton
Rob Geddes	Nick Stringer	Brad Livingston
Jeenu Philip	Allyson Gilliam	Tina Stringer
Jordan Beatty	Mary McKnight	Keri Cunningham
Jim Easter	Brandon	Traci Collier
Tom McCarthy	Laura Bailey	Emily
Joseph Kreps	Matt Leach	Seth Gross
Nick Carter	Rebekah Neal	Leisa Johnson

Robyn Ledbetter	Camora Canty	Jeff Church
Susan DelMonico	Kelli Littlejohn Newman	Cayla Alexander-Moss
Kayla Harrington	Heather Vega	Julie Jordan
Lauren Linna Morgan	Kyle Sexton	Bruce Harris
Joe Jones	Cayla Hicks	Guest
Leigh Ann Ross	Nichole Feagin	Danielle Cole
Anita Ward	Daniel St. Clair	Sheri Connelly
Tara Queen	Caleb Taylor	Misty Gaddis
Laura Boyd	Joyce Ambrose	Thomas Wolsoncroft
Tait Lachney	Pamela Platt	Veronica Hewitt-Potter
John R.	Scott Young	Robert Henslee
Ronda H. Lacey	Milicent Yeager	Bob B.
Jack Wanschek	Carly Wolsoncroft	Taylor Robinson
Jennifer Campbell	Heather Searcy	Rebecca Oliver
Sovanarath Chi	Denise Morris	

1. **INVOCATION AND PLEDGE OF ALLEGIANCE**
   The invocation was given by Mr. Brooklere followed by recitation of the Pledge of Allegiance.

2. **ROLL CALL**
   Executive Secretary Linna called the roll. All nine Board members were present and a quorum was established.

3. **AGENDA**
   President Cobb called for a motion to adopt the agenda. A motion was made by Mr. Brooklere and seconded by Dr. Hicks to adopt the agenda. A roll call vote was taken and the motion to adopt the agenda passed unanimously. No nays or abstentions recorded.

4. **APPROVAL OF MINUTES**
   A motion was made by Mr. Brooklere and seconded by Ms. Giles to approve the July 15, 2026, Board meeting minutes. A vote was taken and the motion to approve the July 15, 2026, Board meeting minutes passed unanimously. No nays or abstentions recorded.

   A motion was made by Mr. Brooklere and seconded by Ms. Giles to approve the July 15, 2026, interview minutes. A vote was taken and the motion to approve the July 15, 2026, interview minutes passed unanimously. No nays or abstentions recorded.

5. **PRESENTATIONS**
   - Ron Hartman, Kristin Brown, and Christy Bolt, after being sworn, gave a presentation on behalf of Tanner Medical Center requesting an out-of-state pharmacy services permit for Tanner Medical Center's hospital in Carrollton, Georgia, to provide remote order verification services for its hospital in Wedowee, Alabama. After a brief discussion, the Board determined that Tanner Medical Center in Carrollton, Georgia, should obtain an out-of-state institutional permit rather than a pharmacy services permit. The Board requested Tanner Medical Center submit an application for an out-of-state institutional permit. The application fee previously submitted for the pharmacy services permit will be applied toward the out-of-state institutional permit application fee.

A motion was made by Ms. Giles and seconded by Mr. Brooklere to approve Tanner Medical Center's out-of-state institutional application upon receipt. A vote was taken and the motion to approve Tanner Medical Center's out-of-state institutional application upon receipt passed unanimously. No nays or abstentions recorded.

- Rachel Burell, after being sworn, gave a presentation on behalf of True North RX requesting a pharmacy services permit. True North RX will provide medication management and healthcare navigation services.

  A motion was made by Ms. Giles and seconded by Mr. Brooklere to approve True North RX's request for a pharmacy services permit. A vote was taken and the motion to approve True North RX's request for a pharmacy service permit passed unanimously. No nays or abstentions recorded.

6. TREASURER'S REPORT

Mr. Brooklere presented the treasurer's report. As of July 31, 2026, total revenues for the fiscal year were 88.22 percent of annual budget. Operating expenses were 75.09 percent of budgeted amounts. Licensing fee revenues were 88.52 percent of budget projections.

A motion was made by Ms. Giles and seconded by Dr. Pinner to accept the treasurer's report. A vote was taken and the motion to accept the treasurer's report passed unanimously. No nays or abstentions recorded.

7. WELLNESS COMMITTEE REPORT

Chief Investigator Casey Shaw gave the Wellness report as follows:

- All individuals being monitored are without complaint and their screens have been negative.
- There are 46 pharmacy health professionals being monitored, which is to be expected based on the number of licensees. This figure is slightly above the number of participants being monitored at the same time last year.

Current work-Pharmacists:

- Five pharmacists are currently in process, either in residential or outpatient treatment, being held out of practice following treatment, or undergoing evaluations.
- One pharmacist has relapsed and is deciding whether to obtain treatment or surrender his/her license. This pharmacist is not working at this time.

Current work-Pharmacy Technicians:

- One pharmacy technician is in process, either in residential or outpatient treatment, being held out of practice following treatment, or undergoing an evaluation.
- Two pharmacy technicians have not accepted nor returned Dr. Garver's calls. He is still calling, leaving messages.

Current work-Pharmacy Students:

- One pharmacy student is in process, either in residential or outpatient treatment, being held out of practice following treatment, or undergoing an evaluation.

8. **CHIEF INVESTIGATOR'S REPORT**
Chief Investigator Casey Shaw gave his report as follows:

- During July 2026, investigators completed 134 compliance inspections. No violations were identified that warranted the filing of a complaint or possible issuance of a statement of charges. From January 1, 2026, through July 30, 2026, investigators completed a total of 953 inspections, with one violation identified for further review.

- During July 2026, the Board received 12 complaints and completed 18 investigations. Of those complaints, two matters were referred to legal counsel for review for possible issuance of a statement of charges for alleged violations of the Pharmacy Practice Act.

- Year to date, the Board has received 131 complaints, nine of which have been referred to legal counsel for further review and possible issuance of statements of charges.

- Since the last Board meeting, two pharmacy burglaries were reported, both occurring in the northern district of the state.

- The two Dodge Durangos purchased by the Board have been delivered and placed into service as part of the ALBOP investigator fleet. Mr. Shaw thanked the Board for its due diligence and continued efforts to keep the vehicle fleet up to date.

- Dr. Anderson prepared a case review committee summary for the Board's review. Of the 117 cases reviewed, 65 cases, or 56 percent, resulted in no violation or action; 32 percent resulted in corrective or educational letters; seven percent resulted in licensee surrenders; four percent were escalated for further investigation or potential issuance of a statement of charges; and one percent were referred to other state agencies or law enforcement agencies.

9. **EXECUTIVE SECRETARY'S REPORT**
Executive Secretary Jon Linna gave his report, which consisted of the following:

- Since the last Board meeting, two pharmacy closures have been reported in Addison and West Blocton.

- The State Committee of Public Health will consider rescheduling medical cannabis from a Schedule I to a Schedule III substance. The earliest the matter could be considered is at the September 2026 meeting. Pharmacists will be allowed to request and receive access to the Medical Cannabis Commission's portal and patient registry.

- The FDA's Pharmacy Compounding Advisory Committee met July 23 and 24 to consider seven peptides for possible inclusion on the 503A bulks list. The committee voted to recommend inclusion of six peptides: BPC-157, KPV, TB-500, MOTS-C, Semax, and Epitalon. Emideltide was not recommended for inclusion. The FDA will review the committee's recommendations and determine whether to include the peptides on the bulks list. There is no required time frame for the FDA to take action following a committee recommendation.

- Board staff received a call from a physician expressing concerns about patients having difficulty filling Suboxone prescriptions. Pharmacies have reported reaching their monthly quotas for dispensing Suboxone due to programs imposed by wholesalers for controlled substance monitoring as required by the DEA. Board staff will continue to work with NABP as it engages with the American Medical Association in response to the recent house of delegates resolution addressing this issue.

- The Partnership for Safe Medicines (PSM) contacted the Board regarding concerns that diverted HIV medications are entering the legitimate drug supply through certain pharmacy-to-pharmacy platforms. PSM may provide a presentation on this issue at a future Board meeting. Pharmacies using pharmacy-to-pharmacy platforms should review the guidance available at safemedicines.org regarding red flags for suspicious products from any supplier.

- NABP is currently onboarding dispensers to the Pulse platform, which offers DSCSA compliance tools, including product verification. Pharmacies can claim their organization profile online through the Pulse online platform at Pulse.Pharmacy.

- Mr. Linna met with members of the Alabama Board of Home Medical Equipment regarding the additional regulatory burden on businesses providing medical oxygen that are required to possess permits from both the Alabama Board of Home Medical Equipment and the Alabama Board of Pharmacy. The Alabama Board of Home Medical Equipment plans to pursue proposed legislation to consolidate permitting under one board.

- Changes in the licensing department have resulted in the following changes:
    - Twalia King will serve as the lead licensing specialist responsible for business licensing, including pharmacy and facility applications.
    - Terry Lawrence will be responsible for pharmacy technician applications and CE audits, as well as assisting with IT needs.
    - Tonya Linville will transition to pharmacist and intern licensing and processing designated representative applications.
    - Dr. Tindle's focus will shift to ongoing system and process improvements, including refinements to the outward-facing Gateway to ThoughtSpan, internal ThoughtSpan workflows, website updates, expanded FAQs, and other guidance.

- Since the inception of the PDMP Compliance Program, outstanding errors have decreased from approximately 78,000 to 6,900 as of the end of July 2026. Mr. Linna encouraged all pharmacists to respond to Vicki Walker's submission error correction requests and to create a PDMP account if they have not done so.

- The Pharmacy Benefit Manager Compliance Division of the Department of Insurance investigates complaints and alleged violations of Alabama's PBM laws. Helpful guidance documents are available through the PBM Compliance Division section of the Alabama Department of Insurance website at pbmcompliance@insurance.alabama.gov.

10. ATTORNEY'S REPORT

- One litigation matter is pending in Montgomery County Circuit Court. Mr. Dettling recommended that the Board enter into a brief executive session to discuss the pending litigation. Dr. Cobb noted that this matter would be taken up at the end of the public meeting.

11. OLD BUSINESS

- A public hearing was held regarding Rule 680-X-2-.50, Civil Penalties. The proposed rule would implement a formal advisory scoring mechanism for the imposition of civil penalties. Two comments were received. Mr. Jeenu Philip provided a public comment during the meeting regarding this rule and Rule 680-X-A. After a discussion, a motion was made by Dr. Pinner and seconded by Ms. Giles to adopt Rule 680-X-2-.50 without change. A vote was taken and the motion to adopt Rule 680-X-2-.50 without change passed with aye votes from Dr. Cobb, Ms. Giles, Mr. Brooklere, Dr. Hicks, Judge Stokes, Ms. Booker, and Dr. Pinner. Dr. Marbury and Dr. Mitchell voted nay. No abstentions recorded.

- A public hearing was held regarding Rule 680-X-A, Appendices. The proposed amendment would implement a civil penalty schedule as mandated by Act 2025-372. Two comments were received. Mr. Jeenu Philip provided a public comment during the meeting regarding this rule and Rule 680-X-2-.50. After a discussion, a motion was made by Mr. Brooklere and seconded by Ms. Giles to adopt Rule 680-X-A without change. A vote was taken and the motion to adopt Rule 680-X-A without change passed with aye votes from Dr. Cobb, Ms. Giles, Mr. Brooklere, Dr. Hicks, Judge Stokes, Ms. Booker, and Dr. Pinner. Dr. Marbury and Dr. Mitchell voted nay. No abstentions recorded.

  RECESS: A brief recess was taken.

- The following rules are currently in the rulemaking process:
  - New Rule 680-X-1-.03, Petition for Declaratory Ruling of the Board, establishes an official process for declaratory rulings. The rule became effective August 14, 2026.
  - New Rule 680-X-1.04, Petition for Adoption, Amendment, or Repeal of a Rule, establishes an official process for adopting, amending, or repealing a rule. The rule became effective August 14, 2026.
  - New Rule 680-X-1-.06, Officers of the Board, outlines the responsibilities of Board officers. The public hearing is scheduled for September 16, 2026. Comments are due to Anne Marie Nolen by close of business on September 15, 2026.
  - New Rule 680-X-1-.07, Meetings of the Board, establishes the framework for Board business meetings. The public hearing is scheduled for September 16, 2026. Comments are due to Anne Marie Nolen by close of business on September 15, 2026.
  - Amendment to Rule 680-X-2-.14, The Role of Technicians in Pharmacies, corrects a statutory citation. The public hearing is scheduled for September 16, 2026. Comments are due to Anne Marie Nolen by close of business on September 15, 2026.

- A draft of Rule 680-X-2-.23, Drug Manufacturers; Wholesale Distributors Private Label Distributors; Repackagers, Third-Party Logistics Providers; Outsourcing Facilities; Reverse

Distributors; and Retail Medical Oxygen Suppliers, was provided to Board members prior to the meeting for review. With no discussion regarding the proposed rule, a motion was made by Ms. Giles and seconded by Dr. Hicks to begin the rulemaking process for Rule 680-X-2-.23 without change. A vote was taken and the motion to begin the rulemaking process for Rule 680-X-2-.23 without change passed unanimously. No nays or abstentions recorded. Comments are due to Anne Marie Nolen by close of business on October 20, 2026. The public hearing will be scheduled for October 21, 2026.

- Mr. Dettling provided Board members with an initial draft of a rule regarding digital signatures at the previous month's meeting. A typographical error was identified in the last sentence to add an "e" and then a period where the word "rule" was incomplete. This proposed rule is intended to comply with the Uniform Electronic Transactions Act. A motion was made by Ms. Giles and seconded by Mr. Brooklere to begin the rulemaking process for the rule regarding digital signatures as amended. A vote was taken and the motion to begin the rulemaking process for the rule regarding digital signatures as amended passed unanimously. No nays or abstentions recorded.

- Mr. Dettling provided Board members with an initial draft of a rule regarding military portability of professional licenses. The proposed rule would expedite the licensing process and fees for service members and their spouses who relocate to Alabama. Following Board review, the rulemaking process could begin as early as the September 16, 2026, meeting.

- The Board discussed the emergency dispensing component of institutional pharmacy Rule 680-X-2-.18. Dr. Nolen reviewed and discussed the revised rule. An amendment was proposed to allow a hospital to dispense a 72-hour, or three-day, supply rather than a 48-hour, or two-day, supply. A motion was made by Ms. Giles and seconded by Dr. Pinner to begin the rulemaking process for Rule 680-X-2-.18 as amended. A vote was taken and the motion to begin the rulemaking process for Rule 680-X-2-.18 as amended passed unanimously. No nays or abstentions recorded.

- CSI Pharmacy presented at the June 17, 2026, Board meeting regarding its request for a nonresident pharmacy services permit. CSI Pharmacy subsequently submitted the requested policies and procedures, which were reviewed and found satisfactory by Mr. Daniel. A motion was made by Ms. Giles and seconded by Dr. Marbury to approve the nonresident pharmacy services permit request. A vote was taken and the motion to approve the nonresident pharmacy services permit passed unanimously. No nays or abstentions recorded.

- The Board discussed the fiscal year 2027 budget. The addition of a legislative consultant was proposed. A motion was made by Mr. Brooklere and seconded by Dr. Hicks to approve the fiscal year 2027 budget with the addition of the legislative consultant. A vote was taken and the motion to approve the fiscal year 2027 budget with the addition of the legislative consultant passed unanimously. No nays or abstentions recorded.

- The Board discussed travel to the NABP Member Forum which will take place from September 30 to October 1, 2026, in Mount Prospect, Illinois. The registration fee is complimentary and NABP pays for travel and lodging for one board member to attend. A motion was made by Ms. Giles and seconded by Dr. Hicks to authorize one Board member to attend the NABP Member Forum. A vote was taken and the motion to authorize one Board member to attend the NABP Member Forum passed unanimously. No nays or abstentions recorded. Board members will check their calendars and advise Mr. Linna if they are available to attend.

12. NEW BUSINESS

- The Joint Committee for collaborative practice agreements met August 17, 2026, and recommended approval of the following collaborative practice agreement applications:
    - Hannah Blevins, Westmeade Pharmacy | Chelsey Stewart, Bridgepoint PC | Test-to-treat services
    - Nicole Genovese, CVS Pharmacy | Jeffrey Coykendall, Oak Street Health | CCM x T2DM, HTN, HLD, and smoking cessation
    - Nicole Genovese, CVS Pharmacy | Kathleen Dupper, Oak Street Health | CCM x T2DM, HTN, HLD, and smoking cessation
    - Nicole Genovese, CVS Pharmacy | Ahmed Mohiuddin, Oak Street Health | CCM x T2DM, HTN, HLD, and smoking cessation
    - Nicole Genovese, CVS Pharmacy | Amanda Walker, Oak Street Health | CCM x T2DM, HTN, HLD, and smoking cessation

  A motion was made by Ms. Giles and seconded by Dr. Hicks to approve the five collaborative practice agreements as presented and approved by the Joint Committee. A vote was taken and the motion to approve the five collaborative practice agreements as presented and approved by the Joint Committee passed unanimously. No nays or abstentions recorded.

- A discussion was held regarding the heavy workloads experienced by pharmacists in pharmacies and the potential for inadequate coverage and/or pharmacist errors. A motion was made by Ms. Giles and seconded by Mr. Brooklere to form a committee, including Board members, to review workload protections for pharmacists and pharmacies for Alabama. A vote was taken and the motion to form a committee, including Board members, to review workload protections for pharmacists and pharmacies for the State of Alabama passed unanimously. No nays or abstentions recorded.

- Dr. Mitchell initiated a discussion regarding receipt of communications related to Board business.

- Board members were provided with proposed dates for 2027 Board meetings. Dr. Cobb encouraged all Board members to review their calendars and the proposed dates in preparation for the September 16, 2026, Board meeting, at which time the 2027 meeting dates will be considered for approval.

- Dr. Cobb announced that he had accepted employment outside the State of Alabama due to the financial constraints of his current employer. Since he will no longer live or work in Alabama, Dr. Cobb announced his resignation from the Alabama Board of Pharmacy, effective September 8, 2026.

Dr. Cobb stated that it had been an honor to serve on the Board and expressed his appreciation to the Board staff and investigators for their work. He also thanked ALSHP for nominating him and the Governor for appointing him to the Board of Pharmacy. He further expressed his appreciation for the opportunity to serve with current and former Board members and thanked Ms. Giles for agreeing to assume the presidency of the Board for the remainder of his term.

Dr. Cobb expressed his deepest appreciation to his wife for her support throughout his tenure, noting that his service presented both professional and personal challenges for him and his family.

13. EXECUTIVE SESSION

A motion was made by Ms. Giles and seconded by Dr. Hicks to enter executive session for the purpose of the nine Board members to discuss pending litigation. Mr. Dettling certified that the purpose of the executive session would be to discuss the legal ramifications and options for pending litigation. An individual voice vote was taken and the motion passed unanimously. No nays or abstentions recorded.

The executive session will begin at 11:35 a.m. and the Board will return to the public hearing at 11:50 a.m. The hearing was recessed at 11:25 a.m. and the public hearing resumed at 12:17 p.m.

14. ADJOURN

The meeting was adjourned at 12:17 p.m.

Stacy S. Giles, Vice President (Presiding)

Jon M. Linna, Executive Secretary

9-16-26

Date